biostudies-literatureShen MZFoundation for Innovative Research Groups of the National Natural Science Foundation of China862526https://www.ebi.ac.uk/biostudies/studies/S-EPMC8981086biostudies-literatureUnknown12<h4>Objective</h4>We aimed to establish a model that can predict refractory/recurrent cytomegalovirus (CMV) infection after haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT).<h4>Methods</h4>Consecutive acute leukemia patients receiving HID HSCT were enrolled (n = 289). We randomly selected 60% of the entire population (n = 170) as the training cohort, and the remaining 40% comprised the validation cohort (n = 119). Patients were treated according to the protocol registered at https://clinicaltrials.gov (NCT03756675).<h4>Results</h4>The model was as follows: Y = 0.0322 × (age) - 0.0696 × (gender) + 0.5492 × (underlying disease) + 0.0963 × (the cumulative dose of prednisone during pre-engraftment phase) - 0.0771 × (CD34+ cell counts in graft) - 1.2926. The threshold oFrontiers in cellular and infection microbiologyA Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation.PMC898108681621001Han WWang FRXu LPChen HWang JZWang JShen MZZhang XHHuang XJYan CHHong SDChen YHMo XDLiu KYWang YfalseA Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation.<h4>Objective</h4>We aimed to establish a model that can predict refractory/recurrent cytomegalovirus (CMV) infection after haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT).<h4>Methods</h4>Consecutive acute leukemia patients receiving HID HSCT were enrolled (n = 289). We randomly selected 60% of the entire population (n = 170) as the training cohort, and the remaining 40% comprised the validation cohort (n = 119). Patients were treated according to the protocol registered at https://clinicaltrials.gov (NCT03756675).<h4>Results</h4>The model was as follows: Y = 0.0322 × (age) - 0.0696 × (gender) + 0.5492 × (underlying disease) + 0.0963 × (the cumulative dose of prednisone during pre-engraftment phase) - 0.0771 × (CD34+ cell counts in graft) - 1.2926. The threshold o2022-01-01T00:00:00Z20222026-05-31T06:01:39.861Z2025-02-19T01:55:19.95ZS-EPMC89810863539261310.3389/fcimb.2022.862526